-Completed initial public offering, raising $258.7 million in gross proceeds, to fund the expanded clinical development of lead product candidate, obexelimab, and support company growth strategy- ...
GSK (GSK) plans to depart the biotechnology industry’s largest trade group, the Biotechnology Innovation Organization, STAT’s John Wilkerson, Lizzy Lawrence, Rachel Cohrs Zhang, and Sarah Owermohle ...
Full Year 2024 Guidance: 7% to 9% sales growth, 11% to 13% profit growth. GSK PLC (NYSE:GSK) reported a 9% sales growth and 19% profit growth year-to-date, reflecting strong performance in ...
To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Sales of GSK’s top-selling vaccines fell sharply during the third quarter amid lower demand ...
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves ...
Will see the 12 quid previous lows, absolutely nothing to warrant buying such a growth-less poorly managed dog index ftse 100 share like gsk. For losers only. My view is that the market is taking ...
Welcome to today's call and webcast. The Q3 presentation was sent to our distribution list by e-mail and you can also find it on gsk.com. Please turn to Slide 2. This is the usual safe harbor ...
The winner will be announced Wednesday evening at The American Lawyer's Industry Awards. These attorneys have been named ...
As one would expect for a gracefully aging institution, the aesthetic of Willamette Week has evolved over the ...
In May 2024, GSK announced positive headline results from the phase III clinical trials SWIFT-1 and SWIFT-2, which assessed the efficacy and safety of depemokimab versus placebo in adults and ...
Moderna to defend against GSK's claims, spokesperson says GSK seeks unspecified monetary damages from Moderna A spokesperson for Massachusetts-based Moderna said the company was aware of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback